智通财经网·2026-01-09 14:34Core Viewpoint - Novo Nordisk's stock price increased by over 3.6% to $59.41 following Amazon Pharmacy's announcement to offer its weight management drug Wegovy in oral form, marking it as the first and only FDA-approved oral GLP-1 medication for weight management in the U.S. [1] Group 1: Product Availability and Pricing - Wegovy oral tablets are now available through Amazon Pharmacy, allowing eligible commercial insurance users to purchase them with a minimum monthly out-of-pocket cost of $25 [1] - For uninsured consumers, a transparent self-pay option is available starting at $149 per month [1] - Amazon Pharmacy's platform enables users to compare insurance payment prices with self-pay prices, automatically applying eligible coupons at checkout [1] Group 2: Delivery and Accessibility - The platform offers fast home delivery of Wegovy oral tablets across all 50 states in the U.S., with same-day delivery available for nearly half of American users [1] Group 3: Market Implications - This development broadens the accessibility of Wegovy and highlights Amazon's strategic expansion into the healthcare and prescription drug distribution sectors [1] - The increasing demand for GLP-1 weight loss drugs, combined with the entry of e-commerce and digital health platforms, may have a profound impact on traditional pharmacies and drug distribution channels [1]